Skip to main content
logo
Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
0.2350
+0.0048 (2.09%)
Aug 21, 2026, 4:00 PM EDT - Market closed

Theriva Biologics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
7.066.426.77.787.576.47
Research & Development
5.318.612.0314.3111.727.8
Operating Expenses
12.3715.0218.7322.0919.2914.27
Operating Income
-12.07-15.02-18.73-22.09-19.29-14.27
Interest & Investment Income
0.30.290.71.440.510.01
Currency Exchange Gain (Loss)
0.010.03-00-0.04-
EBT Excluding Unusual Items
-11.76-14.71-18.04-20.65-18.82-14.27
Merger & Restructuring Charges
-----0.2-
Impairment of Goodwill
---5.59---
Other Unusual Items
0.14-9.03-0.70.66-2.09-
Pretax Income
-11.62-23.74-25.65-19.99-21.11-14.27
Income Tax Expense
----1.64-1.43-
Earnings From Continuing Operations
-11.62-23.74-25.65-18.35-19.69-14.27
Minority Interest in Earnings
-----0
Net Income
-11.62-23.74-25.65-18.35-19.69-14.27
Preferred Dividends & Other Adjustments
1.511.51--0.348.92
Net Income to Common
-13.13-25.25-25.65-18.35-20.03-23.19
Net Income Growth
------
Shares Outstanding (Basic)
31121110
Shares Outstanding (Diluted)
31121110
Shares Change
834.13%800.56%109.24%5.09%25.76%541.07%
EPS (Basic)
-0.42-2.08-19.03-28.48-32.66-47.57
EPS (Diluted)
-0.42-2.08-19.03-28.48-32.66-47.57
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-12.76-16.7-16.94-19.2-19.2-12.9
Free Cash Flow Per Share
-0.41-1.38-12.56-29.80-31.31-26.47
EBITDA
-11.96-14.91-18.59-21.96-19.21-14.19
D&A For EBITDA
0.10.110.140.140.090.09
EBIT
-12.07-15.02-18.73-22.09-19.29-14.27
SEC Filings: 10-K · 10-Q